Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2025-12-01 00:00:00 ET · period of report 2025-11-28 · accession 0001665124-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-01 | 2025-11-28+ | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | S - Sale+OE | $4.58 | -370.2K | 1.01M | -27% | -$1.70M |
| DM | 2025-12-01 | 2025-11-28+ | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | M - OptEx | $1.52 | +370.2K | 1.27M | +41% | +$562.1K |
| DM | 2025-12-01 | 2025-11-28+ | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | M - OptEx | $0.00 | -370.2K | 563.6K | -40% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-28 | S | D | 110,125 | $4.75 | 1,006,439 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2). |
| 2 | Common | Common Stock | 2025-11-28 | M | A | 39,953 | $1.71 | 1,116,564 | D | — | — | |
| 3 | Common | Common Stock | 2025-11-28 | M | A | 70,172 | $0.7 | 1,076,611 | D | — | — | |
| 4 | Common | Common Stock | 2025-12-01 | S | D | 260,047 | $4.51 | 1,006,439 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive. |
| 5 | Common | Common Stock | 2025-12-01 | M | A | 260,047 | $1.71 | 1,266,486 | D | — | — | |
| 6 | Derivative | Employee Stock Option (right to buy) | 2025-11-28 | M | D | 70,172 | $0.00 | 222,683 | D | $0.7 · — to 2033-12-14 | 70,172 Common Stock | (F3) The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. |
| 7 | Derivative | Employee Stock Option (right to buy) | 2025-11-28 | M | D | 39,953 | $0.00 | 823,664 | D | $1.71 · — to 2034-01-02 | 39,953 Common Stock | (F4) 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
| 8 | Derivative | Employee Stock Option (right to buy) | 2025-12-01 | M | D | 260,047 | $0.00 | 563,617 | D | $1.71 · — to 2034-01-02 | 260,047 Common Stock | (F4) 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |